ABCDx awarded Red.IA Salud funding to accelerate development of EmboCheck for pulmonary embolism

– For Immediate Release –

Barcelona / Geneva, 17 November 2026 — ABCDx, a Swiss Spanish MedTech company developing blood-based point-of-care diagnostic solutions for acute care, has been awarded funding through the Spanish Red.IA Salud program for the development of EmboCheck, its next-generation solution for pulmonary embolism.

The project represents an overall programme of approximately €3 million, with around €1.4 million in non-dilutive funding allocated to ABCDx.

Funding acknowledgement. The EmboCheck project is funded by the Ministerio para la Transformación Digital y de la Función Pública through Red.es and co-financed by the European Union through the European Regional Development Fund (FEDER), under the Red.IA Salud programme.

EmboCheck is being developed as a rapid point-of-care solution combining blood biomarkers, clinical information and AI-based risk stratification to support the assessment of patients with suspected pulmonary embolism, particularly in emergency and pre-hospital settings.

The programme will support the further development of the biomarker panel, software and AI components, as well as clinical validation and regulatory activities aimed at progressing EmboCheck toward future CE marking.

"This grant is an important milestone for ABCDx. It gives us the resources to accelerate EmboCheck while further developing the common technology platform behind our acute-care diagnostic products," said Jean-Charles Sanchez, CEO and Co-founder of ABCDx. "Pulmonary embolism remains a major diagnostic challenge, especially when rapid access to laboratory testing or imaging is limited. Our objective is to bring clinically useful information closer to the patient and earlier in the care pathway."

The Red.IA Salud award builds on ABCDx's existing clinical and regulatory programmes for LVOCheck, its blood-based solution for the identification of large-vessel occlusion stroke.

This document contains confidential and proprietary information and is the exclusive property of ABCDx, S.L. Unauthorized use, reproduction, modification, or distribution of this document or its contents is prohibited without the express written consent of ABCDx, S.L.

Together, these programmes reinforce ABCDx's strategy of developing a multi-indication point-of-care diagnostic platform combining biomarkers, lateral-flow technologies, smartphone-based image analysis and clinical algorithms across acute neurological and cardiovascular conditions.

Project visibility and communication

Programme	RedIA Salud · EmboCheck · C006/25-SP · Exp. 2026/0625/00297704
Required website acknowledgement	Funded by the Ministerio para la Transformación Digital y de la Función Pública through Red.es and co-financed by the European Union through the European Regional Development Fund (FEDER).
Social-media references	#FEDER · #RedIASalud · LinkedIn mentions: Red.es; Ministerio para la Transformación Digital y de la Función Pública; Secretaría de Estado de Digitalización e Inteligencia Artificial.

This document contains confidential and proprietary information and is the exclusive property of ABCDx, S.L. Unauthorized use, reproduction, modification, or distribution of this document or its contents is prohibited without the express written consent of ABCDx, S.L.

About ABCDx

ABCDx is a Swiss Spanish MedTech company developing blood-based point-of-care diagnostic solutions for acute and emergency care. Its technology combines biomarkers, lateral-flow assays, smartphone-based image analysis and clinical algorithms to support faster and more objective clinical decision-making.

The company's lead programmes include LVOCheck, for large-vessel occlusion stroke, and EmboCheck, for pulmonary embolism.

ABCDx operates in Switzerland and Spain, with activities spanning biomarker discovery, clinical research, software, AI, regulatory development and point-of-care diagnostics.

RedIA Salud programme

RedIA Salud is a programme managed by Red.es, a public entity attached to the Ministerio para la Transformación Digital y de la Función Pública through the Secretaría de Estado de Digitalización e Inteligencia Artificial, aimed at promoting the application of artificial intelligence solutions in healthcare. With more than €45 million in grants, it is financed by the European Union through the European Regional Development Fund (FEDER), within the Spanish Multi-Regional Operational Programme 2021–2027, and seeks to improve healthcare system efficiency, enhance quality of care, support sustainability and promote technological innovation in the health sector.

Media Contact

Tamara Sefcovicova

PR, Marketing and Office Operations Specialist

tamara.sefcovicova@abcdx.ch

www.abcdx.ch

This document contains confidential and proprietary information and is the exclusive property of ABCDx, S.L. Unauthorized use, reproduction, modification, or distribution of this document or its contents is prohibited without the express written consent of ABCDx, S.L.